Launch your new biological entity!

Benefit from our flexibility and tailor-made approach, learn from AmplyCell broad range of capabilities and strong development expertise

Development of new biological entities cannot always rely on an established roadmap or platform to guide the way to clinical phases. Development of NBE (New Biological Entity) requires thoughtful consideration into the degree of characterization required to enhance molecule understanding and facilitate IMPD and IND approvals.


AmplyCell experts will guide the strategic deployment of clone Quality Control tests, cell banks characterization according to ICH Q5, infra-red and mass spectrometry analytical tests based on your particular objectives.


Orphan drug products may require expertise and a pace of urgency that some collaborators are not prepared to handle alone.